EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2016-10-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/annrheumdis-2016-209775PMID 27697765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting cardiovascular risk in England and Wales : prospective derivation and validation of QRISK 2

  2017cited by this paper
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice.

  2016cited by this paper
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice

  2016cited by this paper
• Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms

  2015cited by this paper
• Cardiovascular events in ankylosing spondylitis: an updated meta-analysis.

  2015cited by this paper
• Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?

  2015cited by this paper
• Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis

  2015cited by this paper
• Mortality in ankylosing spondylitis: results from a nationwide population-based study

  2015cited by this paper
• Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade

  2015cited by this paper
• The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

  2015cited by this paper
• Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: A Consortium of Rheumatology Researchers of North America Registry Study

  2015cited by this paper
• On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study

  2015cited by this paper
• Epicardial adipose tissue thickness in patients with ankylosing spondylitis

  2015cited by this paper
• Rosuvastatin‐Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study

  2015cited by this paper
• An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy

  2015cited by this paper
• The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis.

  2015cited by this paper
• Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink

  2015cited by this paper
• The Impact of Traditional Cardiovascular Risk Factors on Cardiovascular Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

  2015cited by this paper
• The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease

  2015cited by this paper
• Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality

  2015cited by this paper
• Abstract P216: The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis

  2015cited by this paper
• Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta‐Analysis

  2015cited by this paper
• Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism

  2015cited by this paper
• Cardiovascular Risk Profile at the Onset of Psoriatic Arthritis: A Population‐Based Cohort Study

  2015cited by this paper
• Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register

  2014cited by this paper
• A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis

  2014cited by this paper
• Influence of disease activity on the physical activity of rheumatoid arthritis patients.

  2014cited by this paper
• Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study

  2014cited by this paper
• Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

  2014cited by this paper
• Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial

  2014cited by this paper
• Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study

  2014cited by this paper
• The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis

  2014cited by this paper
• Statins Do Not Influence Long-Term Rituximab Clinical Efficiency in Rheumatoid Arthritis Patients

  2014cited by this paper
• The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

  2014cited by this paper
• Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis

  2014cited by this paper
• Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)

  2014cited by this paper
• Glucocorticoid Dose Thresholds Associated With All‐Cause and Cardiovascular Mortality in Rheumatoid Arthritis

  2014cited by this paper
• Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications

  2014cited by this paper
• Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study

  2014cited by this paper
• Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis

  2014cited by this paper
• Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study

  2014cited by this paper
• The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients

  2014cited by this paper
• Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti–Tumor Necrosis Factor‐α Therapy

  2014cited by this paper
• Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention

  2014cited by this paper
• Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis

  2014cited by this paper
• 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

  2014cited by this paper
• The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.

  2014cited by this paper
• Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study

  2014cited by this paper
• Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.

  2014cited by this paper
• Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study

  2013cited by this paper
• Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study.

  2013cited by this paper
• Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

  2013cited by this paper
• Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study

  2013cited by this paper
• Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review

  2013cited by this paper
• Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis

  2013cited by this paper
• The Role of Simvastatin in the Therapeutic Approach of Rheumatoid Arthritis

  2013cited by this paper
• EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

  2013cited by this paper
• SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis

  2013cited by this paper
• Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.

  2013cited by this paper
• Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation

  2013cited by this paper
• Arterial hypertension assessed “out-of-office” in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated “white coat” phenomenon

  2013cited by this paper
• Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study

  2013cited by this paper
• Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis

  2013cited by this paper
• A randomized controlled trial of a cognitive behavioural patient education intervention vs a traditional information leaflet to address the cardiovascular aspects of rheumatoid disease.

  2013cited by this paper
• Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

  2013cited by this paper
• Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

  2013cited by this paper
• Lipid and Lipoprotein Levels and Trend in Rheumatoid Arthritis Compared to the General Population

  2013cited by this paper
• Carotid Plaque Characteristics and Disease Activity in Rheumatoid Arthritis

  2013cited by this paper
• Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.

  2013cited by this paper
• Individualised exercise improves endothelial function in patients with rheumatoid arthritis

  2013cited by this paper
• Disease Factors in Early Rheumatoid Arthritis Are Associated with Differential Risks for Cardiovascular Events and Mortality Depending on Age at Onset: A 10-year Observational Cohort Study

  2013cited by this paper
• Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis.

  2013cited by this paper
• Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.

  2013cited by this paper
• Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study

  2013cited by this paper
• FRI0115 Non-steroidal anti-inflammatory drug use and the risk of cardiovascular disease in patients with rheumatoid arthritis – is there a risk?

  2013cited by this paper
• Primary prevention of cardiovascular disease with a Mediterranean diet.

  2013cited by this paper
• Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis

  2012cited by this paper
• [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)].

  2012cited by this paper
• HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab

  2012cited by this paper
• Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a Pilot Study

  2012cited by this paper
• Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis.

  2012cited by this paper
• Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis.

  2012cited by this paper
• Anti-Tumor Necrosis Factor-&agr; Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis

  2012cited by this paper
• Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: A population‐based study

  2012cited by this paper
• Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden

  2012cited by this paper
• The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population

  2012cited by this paper
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)

  2012cited by this paper
• Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort

  2012cited by this paper
• Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study

  2012cited by this paper
• Depletion of B‐Cells With Rituximab Improves Endothelial Function and Reduces Inflammation Among Individuals With Rheumatoid Arthritis

  2012cited by this paper
• First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

  2012cited by this paper
• Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic

  2012cited by this paper
• Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis

  2012cited by this paper
• High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study

  2012cited by this paper
• Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.

  2012cited by this paper
• Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti–tumor necrosis factor therapy

  2012cited by this paper
• Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis

  2012cited by this paper
• No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment.

  2012cited by this paper
• Increase in ventricular-arterial stiffness in patients with psoriatic arthritis.

  2012cited by this paper
• No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data.

  2012cited by this paper

• Polyarthrite rhumatoïde

  2026cites this paper
• Ecological momentary assessment of daily patient-reported outcomes and actigraphy-measured physical activity and sleep in patients with rheumatoid arthritis and spondyloarthritis: a study protocol

  2026cites this paper
• Heart Failure in Rheumatoid Arthritis: Epidemiology, Pathogenesis, Diagnosis, Treatment, and Emerging Insights-A Comprehensive Review.

  2026cites this paper
• Current status and emerging trends in biological therapies for ankylosing spondylitis: A bibliometric analysis (2004–2024)

  2026cites this paper
• Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.

  2026cites this paper
• Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

  2026cites this paper
• Underestimation of cardiovascular risk by QRISK3 and RA-adapted SCORE2 in a Chinese rheumatoid arthritis population.

  2026cites this paper
• Association between dietary polyunsaturated fatty acids and cardiovascular disease in individuals with rheumatoid arthritis.

  2026cites this paper
• Right ventriculoarterial coupling as a marker of subclinical myocardial damage in rheumatoid arthritis: Comments on the study by Miranda-Aquino et al.

  2026cites this paper
• MARKERS OF SEVERITY IN CHRONIC SYSTEMIC DISEASES: A SYSTEMATIC REVIEW

  2026cites this paper
• The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients

  2026cites this paper
• Cardiovascular Involvement in Autoimmune Rheumatic Diseases

  2026cites this paper
• Risks of Myocardial Infarction and Mortality in Patients with Incident Rheumatoid Arthritis Compared with a Matched General Population: A Danish Nationwide Cohort Study

  2026cites this paper
• Cardiovascular risk factors related to arterial stiffness in patients with rheumatoid arthritis in low disease activity

  2026cites this paper
• Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: a nationwide cohort study in the UK

  2026cites this paper
• The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI.

  2026cites this paper
• Cytokines and multifocal atherosclerosis in rheumatoid arthritis

  2026cites this paper
• Risk factors and surrogate indicators for cardiovascular disease are prevalent in Common Variable Immunodeficiency and associate with inflammatory phenotype

  2026cites this paper
• Subclinical atherosclerosis in rheumatoid arthritis is driven by MicroRNA polymorphisms and NETosis

  2026cites this paper
• Rheumatoid arthritis and stroke risk: a systematic review and meta-analysis

  2026cites this paper
• Review of Literature Investigating the Correlation between Prevalence of Risk Factors Associated with Both Rheumatoid Arthritis and Cardiovascular Diseases

  2026cites this paper
• Impact of anticyclic citrullinated peptide antibody positivity on subclinical cardiovascular profile of patients with established rheumatoid arthritis

  2026cites this paper
• Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

  2026cites this paper
• Exploring cardiovascular risk management implementation in Dutch rheumatoid arthritis patients: insights from rheumatologists and patients

  2026cites this paper
• Patients’ experiences of managing lifestyle habits following a rheumatoid arthritis diagnosis

  2026cites this paper
• Renal Vascular Involvement Assessed by Intrarenal Resistive Index in Patients with Rheumatoid Arthritis: Associations with Structural Joint Damage and Cardiovascular Risk

  2026cites this paper
• Comment on: Similar myocardial infarction characteristics and short-term outcomes in patients with and without inflammatory joint diseases: A nationwide Norwegian study.

  2025cites this paper
• Enhanced mTORC1 Signaling in Inflammatory Monocytes Links Systemic Inflammation to Cardiovascular Disease in Rheumatoid Arthritis

  2025influential citation
• Cardiovascular Risk in Autoimmune Diseases: Mechanisms, Management, and Emerging Evidence

  2025cites this paper
• Impaired cardiorespiratory fitness in psoriatic arthritis: insights from cardiopulmonary exercise testing

  2025cites this paper
• Long-Term Epidemiology of Systemic Sclerosis in Western Australia: A Population-Level Linked Data Study

  2025cites this paper
• A call for caution: interpreting myocardial infarction outcomes in inflammatory joint disease.

  2025cites this paper
• The role of entrepreneurial leadership in advancing economic sustainability: Evidence from Bahraini SMEs

  2025cites this paper
• Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis

  2025cites this paper
• Post-Translational Modifications of Lipoproteins: Emerging Players Linking Inflammation and Cardiovascular Disease in Rheumatoid Arthritis—A Narrative Review

  2025influential citation
• Selection of Common Genes Associated with Rheumatoid Arthritis and Cardiovascular Disease via a Network- and Pathway-Based Approach

  2025cites this paper
• Metabolic challenges of glucose and lipid dysregulation in psoriatic arthritis: a narrative review from pathogenesis to clinical practice

  2025influential citation
• Hypertension, inflammation and vascular risk in inflammatory rheumatic diseases.

  2025cites this paper
• Association between the depression and cardiovascular risk in arthritis patients: a prospective cohort study from the CHARLS database

  2025cites this paper
• Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.

  2025cites this paper
• Impact of axial spondyloarthritis clinical features on cardiovascular risk

  2025cites this paper
• Polyarthrite rhumatoïde

  2025cites this paper
• Myocardial performance index to assess cardiac function in spondyloarthritis: A systematic review and meta-analysis

  2025cites this paper
• Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network

  2025cites this paper
• Performance of the new PREVENT score for indicating subclinical atherosclerosis in rheumatoid arthritis

  2025cites this paper
• Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review

  2025cites this paper
• Management von pulmonalen und kardiovaskulären Komorbiditäten bei rheumatologischen Erkrankungen

  2025cites this paper
• Prevalence and Pathogenetic Mechanisms of Chronic Kidney Disease in Autoimmune-Mediated Systemic Diseases

  2025cites this paper
• The role of sex and systemic inflammation in the development of cardiovascular disease in osteoarthritis: A population-based cohort study using the CLSA.

  2025cites this paper
• Inflammation-Driven Lipid Suppression in Hospitalized Patients: Insights Into the Inflammatory Lipid Paradox From a Retrospective Study

  2025cites this paper
• Efficacy and Safety of the Bushen Quhan Zhiwang Decoction to Achieve Clinical Deep Remission in Rheumatoid Arthritis: Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial

  2025influential citation
• Artrite reumatoide

  2025cites this paper
• Assessing cardiovascular risk in rheumatoid arthritis patients on Janus kinase inhibitors: real-world data from the European Alliance of Associations for Rheumatology-adapted CUORE risk algorithm

  2025influential citation
• Short-term and long-term outcomes in rheumatoid arthritis patients following percutaneous coronary intervention: A systematic review and meta-analysis

  2025cites this paper
• Salidroside: A Potential Drug Candidate to Treat Rheumatoid Arthritis

  2025cites this paper
• Choosing treatment and targeted therapy in axial Spondyloarthritis.

  2025cites this paper
• 2025 Consensus-based recommendations for the referral, diagnosis, monitoring, and management of axial spondyloarthritis in the Arabian Gulf countries.

  2025cites this paper
• The association between cardiometabolic index and rheumatoid arthritis in American adults: the potential mediating role of hypertension, diabetes, and inflammatory markers

  2025cites this paper
• The impact of inflammatory bowel diseases on the development of atherosclerosis and cardiovascular risk.

  2025cites this paper
• The association between abnormal glucose metabolism and rheumatoid arthritis.

  2025cites this paper
• Aortic Regurgitation in a Patient with Rheumatoid Arthritis/Systemic Lupus Erythematosus Overlap Syndrome (Rhupus): Case Report and Review of Literature

  2025cites this paper
• Association between grip and core muscle strength in people with axial spondyloarthritis and healthy controls

  2025cites this paper
• Metabolomics in spondylarthritis

  2025cites this paper
• Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012–2023

  2025cites this paper
• Eccentric Exercise Guidelines for Managing Rheumatoid Arthritis: Findings From a Randomized Controlled Trial

  2025influential citation
• Assessment of Efficacy and Safety of Lipid-Lowering Treatment and Its Importance in Risk Assessment and Prevention in a Hungarian Myositis Cohort

  2025cites this paper
• Challenges of anticoagulation in patients with systemic lupus erythematosus

  2025cites this paper
• Deciphering the Instruction of Low‐Grade Inflammation in the Trajectory of Hyperuricemia and Gout: Perspectives From Healthcare Practitioners

  2025cites this paper
• Expanding the expanded risk score to psoriatic arthritis: any port in a storm

  2025influential citation
• Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply

  2025cites this paper
• Influence of inflammatory bowel diseases on the risk of early atherosclerosis

  2025cites this paper
• Metabolic Consequences of Rheumatoid Arthritis

  2025influential citation
• The Effects of Inflammation and Treatment on Adiposity, Obesity, and Sarcopenia in Patients with Autoimmune Rheumatic Disease

  2025cites this paper
• The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: results from the 10-year prospective CARMA cohort

  2025cites this paper
• Unmasking Subclinical Atherosclerosis: The Impact of Carotid Ultrasound on the Evaluation of Patients With Rheumatoid Arthritis

  2025cites this paper
• Identification of Coronary Morphological Damage in Patients with Chronic Inflammatory Rheumatic Diseases

  2025cites this paper
• Association between bone mineral density and vascular health in rheumatoid arthritis

  2025cites this paper
• Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data.

  2025cites this paper
• Vascular pathology and morphofunctional remodeling of the left heart in rheumatoid arthritis: impact of systemic manifestations and rheumatoid vasculitis

  2025cites this paper
• Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease

  2025cites this paper
• Ocular markers of microangiopathy and their possible association with cardiovascular risk in patients with systemic inflammatory rheumatic diseases: a systematic review

  2025cites this paper
• Factores de riesgo cardiovascular relacionados con rigidez arterial en pacientes con artritis reumatoide en actividad baja de la enfermedad

  2025cites this paper
• Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial

  2025cites this paper
• Prediction of abnormal bone mass with a pericoronary adipose tissue Attenuation model

  2025cites this paper
• Frequency of Metabolic Syndrome in Individuals Diagnosed with Rheumatoid Arthritis and Its Relationship with Inflammatory Parameters

  2025cites this paper
• Effects of Tofacitinib Therapy on Circulating Tumour-Associated Antigens and Their Relationship with Clinical, Laboratory and Vascular Parameters in Rheumatoid Arthritis

  2025cites this paper
• Quality improvement project to improve cardiovascular risk screening in patients with rheumatoid arthritis

  2025cites this paper
• Greater pain and functional impairment in chronic erosive hand osteoarthritis compared to treated rheumatoid arthritis: A comparative study

  2025cites this paper
• Bridging the gut and the heart-Exploring pathophysiology, risk factors, and therapeutic implications of cardiovascular disease in inflammatory bowel disease

  2025cites this paper
• Similar myocardial infarction characteristics and short-term outcomes in patients with and without inflammatory joint diseases: A nationwide Norwegian study.

  2025cites this paper
• Higher frequencies of age-associated B-cells in early arthritis are linked to atherosclerosis and immune circuits-a potential role as a biomarker for risk stratification.

  2025cites this paper
• Unveiling Sex-Related Variability in Psoriatic Arthritis: A Call for Personalized Care

  2025cites this paper
• Safety profile of JAK inhibitors in inflammatory or autoimmune diseases.

  2025cites this paper
• Low adherence to cardiovascular risk assessment guidelines in patients with rheumatoid arthritis: a retrospective chart review of routine clinical practice

  2025influential citation
• Cardiovascular risk in psoriatic arthritis: How can we manage it?

  2025cites this paper
• Soluble interleukin-33 receptor (sST-2): a novel marker for assessing cardiovascular risk in rheumatoid arthritis

  2025cites this paper
• Oscillometric, greyscale- and novel color-Doppler-ultrasound indices of macrovascular damage in Sjögren’s: the SICARD cohort study

  2025influential citation
• Cardio-rheumatology: present and future. Part II

  2025cites this paper
• The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties

  2025cites this paper
• Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars

  2025cites this paper